| Product Code: ETC6738641 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China CINV Existing and Pipeline Drugs Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China CINV Existing and Pipeline Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 China CINV Existing and Pipeline Drugs Market - Industry Life Cycle |
3.4 China CINV Existing and Pipeline Drugs Market - Porter's Five Forces |
3.5 China CINV Existing and Pipeline Drugs Market Revenues & Volume Share, By Major Drug, 2021 & 2031F |
4 China CINV Existing and Pipeline Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chemotherapy-induced nausea and vomiting (CINV) cases in China |
4.2.2 Growing adoption of advanced and effective CINV drugs in the market |
4.2.3 Favorable government initiatives and policies supporting the development and accessibility of CINV drugs |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new drugs in China |
4.3.2 Competition from existing drugs and alternative therapies for CINV management |
5 China CINV Existing and Pipeline Drugs Market Trends |
6 China CINV Existing and Pipeline Drugs Market, By Types |
6.1 China CINV Existing and Pipeline Drugs Market, By Major Drug |
6.1.1 Overview and Analysis |
6.1.2 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By Major Drug, 2021- 2031F |
6.1.3 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By Aloxi (Palonosetron), 2021- 2031F |
6.1.4 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By Zofran Generic (Ondansetron), 2021- 2031F |
6.1.5 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By Kytril Generic (Granisetron), 2021- 2031F |
6.1.6 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By Emend (Aprepitant), 2021- 2031F |
6.1.7 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By Akynzeo (Netupitant-Palonosetron), 2021- 2031F |
6.1.8 China CINV Existing and Pipeline Drugs Market Revenues & Volume, By SUSTOL (Extended Release Granisetron Injection), 2021- 2031F |
7 China CINV Existing and Pipeline Drugs Market Import-Export Trade Statistics |
7.1 China CINV Existing and Pipeline Drugs Market Export to Major Countries |
7.2 China CINV Existing and Pipeline Drugs Market Imports from Major Countries |
8 China CINV Existing and Pipeline Drugs Market Key Performance Indicators |
8.1 Research and development investment in novel CINV drugs |
8.2 Patient adherence and satisfaction rates with existing and pipeline CINV drugs |
8.3 Clinical trial success rates for new CINV drug candidates |
8.4 Number of partnerships and collaborations for drug development in the CINV market |
8.5 Adoption rates of innovative drug delivery mechanisms for CINV treatment in China |
9 China CINV Existing and Pipeline Drugs Market - Opportunity Assessment |
9.1 China CINV Existing and Pipeline Drugs Market Opportunity Assessment, By Major Drug, 2021 & 2031F |
10 China CINV Existing and Pipeline Drugs Market - Competitive Landscape |
10.1 China CINV Existing and Pipeline Drugs Market Revenue Share, By Companies, 2024 |
10.2 China CINV Existing and Pipeline Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here